# The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen

## Authors

- Chinwe Ewenighi ([ORCID](https://orcid.org/0000-0003-2267-8421)) — Medical Laboratory Science Department, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria
- Uchechukwu Dimkpa ([ORCID](https://orcid.org/0000-0003-1727-3622)) — Physiology Department , Nnamdi Azikiwe University, Awka, Nnewi Campus Anambra State, Nigeria
- Joel Onyeanusi ([ORCID](https://orcid.org/0009-0004-0768-9127)) — Medical Laboratory Science Department, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria
- Linus Onoh ([ORCID](https://orcid.org/0009-0000-5114-0060)) — Dept. of Community Medicine, Enugu State University of Science and Technology, Enugu, Nigeria
- Gladys Onoh ([ORCID](https://orcid.org/0009-0002-8054-8692)) — Nursing Science Deptment, Ebonyi State University, Abakaliki, Ebonyi Nigeria.
- Nma Oti — Medical Laboratory Science Department, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria
- Linda Obasi — Medical Laboratory Science Department, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria
- Uchechukwu Ezeugwu ([ORCID](https://orcid.org/0009-0002-1851-4029)) — Department of Physiotherapy, University of Nigeria Teaching Hospital, Enugu, Nigeria.

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 1, Issue 2 (2015), pages 31–35
- **Article type:** Original Research
- **Published online:** 2015-06-27
- **DOI:** [10.5455/umj.20150518015721](https://doi.org/10.5455/umj.20150518015721)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=188729
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/188729.pdf

## Abstract

Aim: To evaluate the diagnostic performance of free-total PSA ratio using the criteria of total PSA > 4.0 ng/ml as the cut-off for prostate cancer diagnosis in men. Method: A total of sixty patients (mean age 58.03 ± 9.82) were recruited as test subjects from the cancer unit of National Obstetric Fistula Center (NOFIC), Abakaliki, Ebonyi State, Nigeria. All the patients had total PSA value above 4.0ng/ml. Free and total PSA estimations were done using the principle of Enzyme Linked Immunosorbent Assay (ELISA). Result: Free-total PSA ratio indicated high sensitivity (98.2% and 98.2%), specificity (87.9% and 82.9%) and positive predictive values (93.3% and 90%) for detecting undiagnosed prostate cancer at cut-offs of 0.25 and 0.19 respectively. High sensitivity (97.6%) and moderate specificity (61.7%) and positive predictive value (70.0%) were observed at cut off of 0.10. Using the free-total PSA ratio cut-off of ≤ 0.10 for prostate cancer, 70% of the test subjects were diagnosed of prostate cancer, on the other hand when a cutoff of > 0.25 was used, 6.7% of the test subjects were diagnosed of a possible benign prostatic hyperplasia. Conclusion: Free-total PSA ratio is a highly sensitive, specific and useful diagnostic tool alternative to total PSA assay for the screening of undiagnosed prostate cancer. Furthermore, it is highly predictive of the risk for developing prostate cancer at specific cutoff levels.

## Keywords

: Prostate-Specific Antigen (PSA); Free-Total PSA Ratio; Prostate Cancer

## How to cite

Ewenighi C, Dimkpa U, Onyeanusi J, Onoh L, Onoh G, Oti N, et al. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. Ulutas Med J. 2015;1(2):31-35. doi:10.5455/umj.20150518015721

## References

1. National Cancer Institute. Prostate specific antigen test. Reviewed 2012. Accessed from http:// www.cancer.gov/PSA on 11th May, 2014.
2. Hoffman RM, Clannon DL, Littenberg B, Frank JJ, Pierce JC. Using the free to total prostate specific antigen ratio to detect prostate cancer in men with non-specific elevations of prostate specific antigen level. J Gen Intern Med. 2000; 15 (10):739-748. https://doi.org/10.1046/j.1525-1497.2000.90907.x
3. Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem. 1991; 37:1618-25. https://doi.org/10.1093/clinchem/37.9.1618
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O, et al. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51:222-6.
5. Christensson A, Laurell CB, Lilja H, et al. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755-63. https://doi.org/10.1111/j.1432-1033.1990.tb19466.x
6. McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995; 45:729– 44. https://doi.org/10.1016/s0090-4295(99)80076-4
7. Lilja H, et al. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Suppl. 1995; 220:47–56.
8. Leinonen J, Lövgren T, Vornanen T, Stenman UH, et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1-antichymotrypsin. Clin Chem. 1993; 39:2098– 103. https://doi.org/10.1093/clinchem/39.10.2098
9. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol.1993; 150(1):100– 105.. https://doi.org/10.1016/s0022-5347(17)35408-3
10. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP, et al. Defining and updating the American Cancer Society guidelines for the cancer related check-up: prostate and endometrial cancers. CA Cancer J Clin. 1993; 43:42–6. https://doi.org/10.3322/canjclin.43.1.42
11. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. Baltimore, Md: Williams & Wilkins; 1992. In: American Urological Association 1992 Policy Statement Book.
12. PDQ. (Physician Data Query) [Database online]. Bethesda, Md: National Cancer Institute: 1984 – [updated 9/99]. Screening for prostate cancer. Available from: National Cancer Institute; National Library of Medicine, Bethesda, Md: CDP Technologies, Inc., New York, NY; Lexis-Nexis, Miamisburg, Ohio.
13. American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997; 126:480–4.
14. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
15. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New England Journal of Medicine. 2004; 350(22):2239-2246. https://doi.org/10.1056/nejmoa031918
16. Vessella RL, Lange PH, et al. Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am. 1997; 24:261–8. https://doi.org/10.1016/s0094-0143(05)70371-2
17. Walz J, Haese A, Scattoni A, et al. Percent Free Prostate-Specific Antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and Lower. Cancer. 2008; 113 (10):2695-2703. https://doi.org/10.1002/cncr.23885
18. Demura H, Nakamura M, Hasumi H, et al. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy. Int J Urol. 2004; 11(7):494-500.
19. Mitrunen K, Pettersson K, Piironen T, et al. A novel dual-label one-step immunoassay for simultaneous measurement of free and total PSA concentrations and ratios in serum. Clin Chem 1995; 41:1115-1120. https://doi.org/10.1093/clinchem/41.8.1115
20. Demura T, Shinohara N, Tanaka M, et al. Ratio of free and total prostate-specific antigen: A method of detecting prostate cancer in the cases with PSA levels of 10ng/mL or lower. J Urol. 1996; 155(suppl):S368A.
21. Mione R, Barioli P, Barichello M, Zattoni F, Prayer-Galetti T, Plebani M, Aimo G, Terrone C, Manferrari F, Madeddu G, Caberlotto L, Fandella A, Pianon C, Vianello L, Gion M. Prostate cancer probability after total PSA and percent free PSA determination. Int J Biol Markers. 1998; 13(2):77-86. https://doi.org/10.1177/172460089801300203
22. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine. 2012; 366(11):981-990 https://doi.org/10.1056/nejmx120029
23. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151:1283–90. https://doi.org/10.1016/s0022-5347(17)35233-3
24. Thiel RE, Oesterling JE, Wojno KJ, et al. A multicenter comparison of the diagnostic performance of free PSA. Urology 48(6A suppl):S45-S50, 1996. https://doi.org/10.1016/s0090-4295(96)00609-7
25. Bangma CH, Rietbergen BW, Kranse R, et al. The free-to - total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol. 1997; 157:2191-2196. https://doi.org/10.1016/s0022-5347(01)64712-8
26. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995; 154:1090-1095. https://doi.org/10.1016/s0022-5347(01)66984-2
